Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review

Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review

Programmed cell death 1 (PD-1) blockade is considered contraindicated in liver transplant (LT) recipients due to potentially lethal consequences of graft rejection and loss. Though post-transplant PD-1 blockade had already been reported, pre-transplant use of PD-1 blockade has not been thoroughly in...

Full description

Bibliographic Details
Main Authors: Zi-yun Qiao, Zi-jie Zhang, Zi-cheng Lv, Huan Tong, Zhi-feng Xi, Hao-xiang Wu, Xiao-song Chen, Lei Xia, Hao Feng, Jian-jun Zhang, Qiang Xia
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Immunology
Subjects:
programmed cell death 1 (PD-1) inhibitor
liver transplant
hepatocellular carcinoma
allograft rejection
neoadjuvant immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.653437/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.653437/full

Similar Items